CIK 0000874015
- Large accelerated filer
IONIS PHARMACEUTICALS INC
Sign in to watch- Ticker
- IONS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 330336973
- Phone
- +1 760-931-9200
- Business address
- 2855 GAZELLE COURT, CARLSBAD, CA, 92010
- Former names
- ISIS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $148,200
- in 1 filing
- Open-market sales, last 90 days
- $61,389
- in 2 filings
Net +$86,811. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-03 | LOSCALZO JOSEPH Director | Option exercise | +16,000 | $24.42 | $391K | 52,330 |
| 2025-09-03 | LOSCALZO JOSEPH Director | Sale | −16,000 | $60.15 | $962K | 36,330 |
| 2025-09-03 | LOSCALZO JOSEPH Director | Option exercise · Non-Qualified Stock Option (right to buy) | −16,000 | 0 | ||
| 2025-09-03 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Option exercise 10b5-1 | +19,658 | $53.77 | $1.1M | 71,165 |
| 2025-09-03 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Sale 10b5-1 | −12,455 | $60.46 | $753K | 58,710 |
| 2025-09-03 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Sale 10b5-1 | −7,203 | $61.42 | $442K | 51,507 |
| 2025-09-03 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −19,658 | 0 | ||
| 2025-09-02 | Swayze Eric EVP Research | Sale 10b5-1 | −10,000 | $49.22 | $492K | 38,432 |
| 2025-09-02 | Swayze Eric EVP Research | Sale 10b5-1 | −1,130 | $53.68 | $61K | 37,302 |
| 2025-09-02 | WENDER JOSEPH H Director | Sale 10b5-1 | −11,200 | $55.04 | $616K | 125,635 |
| 2025-09-02 | WENDER JOSEPH H Director | Sale 10b5-1 | −5,600 | $57.53 | $322K | 120,035 |
| 2025-09-02 | PARSHALL B LYNNE Director | Sale 10b5-1 | −10,750 | $50.42 | $542K | 75,594 |
| 2025-09-02 | PARSHALL B LYNNE Director | Sale 10b5-1 | −9,250 | $51.49 | $476K | 66,344 |
| 2025-09-02 | Geary Richard S EVP, Chief Development Officer | Sale 10b5-1 | −10,000 | $50.37 | $504K | 79,657 |
| 2025-09-02 | WENDER JOSEPH H Director | Sale 10b5-1 | −11,200 | $55.04 | $616K | 125,635 |
| 2025-09-02 | WENDER JOSEPH H Director | Sale 10b5-1 | −5,600 | $57.53 | $322K | 120,035 |
| 2025-09-02 | O'NEIL PATRICK R. EVP CLO & General Counsel | Option exercise 10b5-1 | +13,050 | $32.60 | $425K | 70,180 |
| 2025-09-02 | O'NEIL PATRICK R. EVP CLO & General Counsel | Sale 10b5-1 | −13,050 | $54.51 | $711K | 57,130 |
| 2025-09-02 | O'NEIL PATRICK R. EVP CLO & General Counsel | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −13,050 | 17,517 | ||
| 2025-09-02 | BENNETT C FRANK EVP, Chief Scientific Officer | Sale 10b5-1 | −5,000 | $49.14 | $246K | 88,679 |
Page 27 of 34 · 668 trades